Cross Country Healthcare faces a challenging transition as it navigates a post-pandemic market contraction, evidenced by a 17.8% year-over-year revenue decline in 2026Q1. While the company maintains a fortress balance sheet with a negligible 0.01 debt-to-equit...
Price trend, volume and key moving averages
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q2 2026Latest May 7, 2026 | -$0.03+40.0% vs -$0.05 | $241M+1.7% vs $237M |
Q2 2026 Mar 4, 2026 | -$0.06-300.0% vs $0.03 | $237M-6.9% vs $254M |
Q4 2025 Nov 12, 2025 | $0.03-25.0% vs $0.04 | $250M-1.7% vs $254M |
Q3 2025 Aug 6, 2025 | -$0.01-114.3% vs $0.07 | $274M-6.7% vs $294M |
Cross Country Healthcare NASDAQ: CCRN stockholders approved the company's proposed merger agreement at a virtual special meeting held July 16, according to remarks delivered during the meeting by Kevin Clark, the company's co-founder, CEO and chairman of the board.
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Cross Country Healthcare, Inc. (NASDAQ: CCRN) to Knox Lane for $13.25 per share in cash.Halper Sadeh encourages Cross Country shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or [email protected] or [email protected] investigation concerns whether Cross Country and its board of direct.
Benchmark CCRN against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Cross Country Healthcare, Inc. (CCRN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $13.25 | $428.06M | -4.52 | -21.56% | -9% | -25.57% | — | |
| $34.54 | $1.34B | -13.93 | -8.49% | 3.06% | 15.31% | — | |
| $9.94 | $302.22M | -6.17 | 3.1% | -3.35% | -20.78% | — | |
| $21.57 | $1.48B | 26.63 | 7.08% | 6.59% | 24.12% | — | |
| $16.66 | $577.59M | -2.30 | -1.87% | -6.73% | -27.06% | — | |
| $57.63 | $2.68B | -198.72 | 0.58% | 0.56% | 5.06% | — |
Cross Country Healthcare, Inc. (CCRN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Cross Country Healthcare, Inc. (CCRN) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 28, 2026·SEC
Jul 17, 2026·SEC
Jul 6, 2026·SEC
Get notified when CCRN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Cross Country Healthcare, Inc. (CCRN) stock FAQ — growth, dividends, profitability & financials explained
Cross Country Healthcare, Inc. (CCRN) reported $1.00B in revenue for fiscal year 2025. This represents a 417% increase from $193.8M in 1999.
Cross Country Healthcare, Inc. (CCRN) saw revenue decline by 21.6% over the past year.
Cross Country Healthcare, Inc. (CCRN) reported a net loss of $98.6M for fiscal year 2025.
Cross Country Healthcare, Inc. (CCRN) has a return on equity (ROE) of -25.6%. Negative ROE indicates the company is unprofitable.
Cross Country Healthcare, Inc. (CCRN) generated $39.6M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
